Novo CEO pressed by Senate to chop prices of obesity, diabetes medicine CEO Lars Fruergaard Jørgensen informed lawmakers the corporation would consider new talks with insurers in regards to the listing price ranges of Wegovy and copyright if they pledge to keep the medicines on their formularies. Previously this summer https://kethek.com/